|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||363.461 g·mol−1|
|3D model (JSmol)|
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity. It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.
- "formularyjournal.modernmedicine.com". Archived from the original on 2012-03-04.
- Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR (January 1998). "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology. 56 (1): 30–6. doi:10.1159/000028179. PMID 9467185. S2CID 46848815.
- "FDA rejects bucindolol and questions trial integrity « CardioBrief". 2 June 2009.